Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003141 | 0.89 | CSNK2A2 (0.45) | CRHR1HPGDSMN1; SMN2MEN1LMNA | |
| SCHEMBL1004408 | 0.76 | HPGD (0.45) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL1004853 | 0.76 | HPGD (0.46) | HPGDSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL1003369 | 0.75 | HPGD (0.69) | CRHR1HPGDSMN1; SMN2MEN1LMNA | |
| SCHEMBL13306259 | 0.74 | TPMT (0.52) | HPGDSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5427089 | 0.73 | HSD17B1 (0.44) | CRHR1HPGDMEN1LMNAKMT2A | |
| SCHEMBL15979606 | 0.73 | RIPK1 (0.43) | — | |
| SCHEMBL21077963 | 0.72 | CDK4 (0.50) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL15218744 | 0.71 | HDAC6 (0.44) | SMN1; SMN2HDAC6 | |
| SCHEMBL12852626 | 0.70 | NAMPT (0.40) | CRHR1NPSR1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8535560-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2011008664-A2 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | POU2F1, POU2F2, POF1B | CRHR1 3986/4885HPGD 3260/4885SMN1; SMN2 1017/4885 |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | POU2F1, POU2F2, POF1B | CRHR1 3986/4885HPGD 3260/4885SMN1; SMN2 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.